4 Stocks Taking Charge

ASX Stocks

Four stocks from varied sectors trading at less than a dollar and taking charge on the Australian stock exchange are discussed herein. With S&P/ASX 200 also closing higher at 6176.3 up by 30.23 points these stocks are worth looking at.

CAULDRON ENERGY LIMITED (ASX: CXU) – The profit of the Consolidated Entity after providing for income tax amounted to $173,299 as at 30 June 2018, as compared to $11,954,682 loss as at 30 June 2017. The directors do not recommend the payment of a dividend and no amount has been paid or declared by way of a dividend to the date of this report. With the available cash and cash equivalents at end of financial year 2018 on $1.9 million the company represents decent liquidity. The execution of a farm-in agreement (Agreement) with Oceltip Metals Pty Ltd (Oceltip) has been recently announced by the company. The stock has surged by 19.355% to $0.037 as at October 4, 2018. It has undergone a performance change of 10.71% over the last one month.

RUBICOR GROUP LIMITED (ASX: RUB) – About 5.3% below the previous year, the company’s revenue for the year was $189.1 million which is consistent with the disposal of the group’s 51% shareholding in Ensure Group in April 2017. Compared with a $14.6 million profit the previous year, statutory EBITDA decreased to a $1.2 million loss. This was largely due to the reversal of deferred tax assets and impairment of assets. Compared to the profit in FY 2017 of $15.5 million, the company reported a statutory loss after-tax of $13.6 million. With available cash at 30 June 2018 was $0.6 million down from $2.0 million FY2017. The stock has surged by 22.222% to $0.022 as at October 4, 2018 very close to its 52-week low. It has undergone a performance change of -21.74% over the last one month. 

BIGTINCAN HOLDINGS LIMITED (ASX: BTH) – For BTH FY18 was a successful year with strong growth in all areas of the business. Annualized Recurring Revenue (ARR) up 41% from June 2017, hit a record of $15.4m at June 2018. Total revenue was up by 42% of $13.1m for FY18, and the net loss after tax was broadly in line with forecasts of $6.6m. Given the desire to continue investing in the business the Board has not declared any dividend this year. With over 90% of revenue earned outside Australia, in FY18 statutory operating revenue of $ 13.1m was up 42% on FY17. The stock has surged by 8.451% to trade at $0.385 as at October 4, 2018. It has undergone a positive performance change of 12.70% over the last one month.

G MEDICAL INNOVATIONS HOLDINGS LIMITED (ASX: GMV) – The Company has recently entered into a Controlled Placement Agreement (CPA) with Acuity Capital. Over the coming 28-month period, the CPA provides the company with up to AUD$10 million of standby equity capital. The revenue from ordinary activities has increased 100% to $1.001 million. The Company had a net loss of US$ 8.509 million versus US$ 21.740 million in the comparable period of 2017. For the half-year ended 30 June 2018, no dividend has been paid or recommended to be paid. With available cash and cash equivalents at the end of the period of $3.204 million the company represents a healthy balance sheet position. The stock has surged by 12.857% to trade at $0.395 as at October 4, 2018. It has undergone a positive performance change of 6.06% over the last one month.

Dividend Stocks To Buy

Sponsored ad by Kalkine

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Facebook Comments

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report

LEAVE A REPLY

Please enter your comment!
Please enter your name here